LTK
ENSG00000062524
Target class
Kinase
Chromosome
15
- Chemical probe available
- No
- Other names
- TYK1
- Target name
- LTK
- Gene name
- Leukocyte receptor tyrosine kinase
- Gene symbol
- LTK
- Protein name
- Leukocyte tyrosine kinase receptor (EC 2.7.10.1) (Protein tyrosine kinase 1)
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 29
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 28.58
- Tissue specificity (Gini)
- 0.606
- Tissue specificity (tau)
- 0.935
- KEGG gene identifiers
- hsa:4058
- Reactome pathways
- R-HSA-9842663
- Protein interaction confidence
- 0.89
- Protein interaction partners
- 3
- End position
- 41513887
- Start position
- 41503634
- Chromosome
- 15
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein .
- Vesicles
Publication evidence
- PubMed 34646012
- Tissue specificity (tau)
- 0.934867
- Expression inequality (Gini)
- 0.605723
Expression in transcripts per million
- Lung
- 28.58
- Spleen
- 10
- Small Intestine - Terminal Ileum
- 7.58
- Colon - Transverse
- 6.41
- Testis
- 6.32
Expression in transcripts per million
- Lung28.58
- Spleen10
- Small Intestine - Terminal Ileum7.58
- Colon - Transverse6.41
- Testis6.32
- Stomach4.61
- Brain - Cortex4.46
- Brain - Cerebellum4.25
- Kidney - Cortex4.11
- Colon - Sigmoid3.88
- Minor Salivary Gland3.46
- Kidney - Medulla2.8
- Brain - Frontal Cortex (BA9)2.8
- Cervix - Endocervix2.45
- Brain - Cerebellar Hemisphere2.37
- Liver2.07
- Brain - Caudate (basal ganglia)1.82
- Thyroid1.63
- Whole Blood1.48
- Vagina1.46
- Brain - Anterior cingulate cortex (BA24)1.43
- Cervix - Ectocervix1.39
- Adipose - Visceral (Omentum)1.33
- Heart - Atrial Appendage1.32
- Brain - Putamen (basal ganglia)1.26
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007165
- GO:0007169
- GO:0008283
- GO:0010666
- GO:0010976
- GO:0038083
- GO:0043066
- GO:0051897
- GO:0071300
- GO:0005886
- GO:0016020
- GO:0004672
- GO:0004713
- GO:0004714
- GO:0005515
- GO:0030298
heart disease
Studies
- preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Activation of leukocyte receptor tyrosine kinase results in cardiac hypertrophy and cardiomyocyte degeneration
Biological samples
- cardiovascular system
PubMed 21283106
Related records
Trials (130)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
- A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
- A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
- A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
- A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
- A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
- A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Drugs (2)
- Gilteritinib
- Lorlatinib